Key Highlights
● Addex Therapeutics announced in a 6-K filed September 25, 2026 that it regained full global rights to its GABAB positive allosteric modulator portfolio for substance use disorders from Indivior UK Limited.
● Indivior returned the rights as part of an R&D rationalization tied to its planned Merger with Supernus Pharmaceuticals, and the filing discloses no financial terms tied to the reversion.
● CEO Tim Dyer said Addex can now evaluate strategic Options including new partnerships or advancing the programs further, with potential applications beyond substance use disorders in pain, overactive bladder and neurodevelopmental disorders.
● The Geneva-based clinical-stage biopharmaceutical company trades on Nasdaq under the ticker ADXN and did not disclose a development timeline or its current cash position for funding the returned program.
Addex Therapeutics (NASDAQ:ADXN) announced in a 6-K filed September 25, 2026 that it has regained full global rights to its GABAB positive allosteric modulator portfolio for substance use disorders from Indivior UK Limited, after Indivior undertook an R&D rationalization ahead of its planned merger with Supernus Pharmaceuticals. The Swiss biopharmaceutical company said the reversion gives it complete ownership of the development candidate and the freedom to pursue it, and related science, independently.
What Addex Gets Back
According to the press release furnished as Exhibit 99.1, Indivior had partnered with Addex to develop GABAB positive allosteric modulators, or PAMs, specifically for substance use disorders. With Indivior returning those rights, Addex now holds full global rights to the GABAB PAM development candidate that had been part of that collaboration, in addition to its own proprietary GABAB PAM program that it had already been advancing for chronic cough. The filing frames this as consolidating two related GABAB Assets under Addex's sole control.
Why Indivior Gave the Rights Back
The filing ties Indivior's decision to a broader research-and-development rationalization at that company, occurring as Indivior pursues a planned merger with Supernus Pharmaceuticals. Neither the 6-K nor the press release provides additional detail on Indivior's internal rationale beyond describing it as part of this R&D rationalization, nor does either document disclose any financial terms, such as payments made or owed between the two companies in connection with the reversion of rights.
What Addex Plans to Do With It
CEO Tim Dyer said in the press release that these GABAB PAM assets reflect years of world-class research in allosteric modulation and build on a biological approach clinically validated by baclofen, a reference to an existing GABAB-targeting therapy used in other indications. Dyer added that Addex can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering. The company said it intends to explore potential applications of its now-expanded GABAB portfolio beyond substance use disorders, citing pain, overactive bladder and neurodevelopmental disorders as areas of interest, alongside its existing chronic cough program.
The Company's Business
Addex Therapeutics is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that focuses on developing allosteric modulator drugs, a class of compounds that bind to receptors at sites other than the primary active site to fine-tune their activity. Its shares trade on Nasdaq under the ticker ADXN. The filing does not disclose a specific development timeline or next clinical milestone for the returned GABAB substance use disorder candidate now that Addex holds it outright.
A Small Biotech Regaining Leverage
For a clinical-stage company of Addex's size, regaining full rights to a partnered asset can cut both ways: it removes a source of milestone or Royalty payments that might otherwise have come from Indivior as the program advanced, but it also frees Addex to negotiate a new Partnership on its own terms, potentially after generating additional data that could increase the asset's value. The filing does not disclose Addex's current cash position or how it intends to fund further development of the GABAB substance use disorder candidate in the near term, leaving open whether the company plans to advance it internally before seeking a new partner or move directly to out-licensing discussions.
Signposts for the Reclaimed Program
Key items to track include whether Addex signs a new partnership for the GABAB PAM substance use disorder candidate, and any disclosed timeline for advancing the program independently before seeking a partner. The progress of Indivior's planned merger with Supernus Pharmaceuticals is also relevant context, alongside updates on Addex's existing GABAB PAM program for chronic cough.






Please wait processing your request...